Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $12.05 USD
Change Today +0.24 / 2.03%
Volume 309.7K
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

tokai pharmaceuticals inc (TKAI) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/17/14 - $30.00
52 Week Low
10/10/14 - $9.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tokai pharmaceuticals inc (TKAI) Related Businessweek News

No Related Businessweek News Found

tokai pharmaceuticals inc (TKAI) Details

Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate, galeterone, is a multi-targeted, oral small molecule being developed for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. The company was founded in 2004 and is based in Boston, Massachusetts.

17 Employees
Last Reported Date: 03/26/15
Founded in 2004

tokai pharmaceuticals inc (TKAI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $608.5K
Chief Financial Officer
Total Annual Compensation: $201.7K
Chief Medical Officer and Head of Research & ...
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2014.

tokai pharmaceuticals inc (TKAI) Key Developments

Tokai Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Tokai Pharmaceuticals, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $8,982,000 compared with $5,885,000 for the same period a year ago. Net loss was $8,957,000 or $0.40 per basic and diluted share compared with $5,851,000 or $11.68 per basic and diluted share for the same period a year ago. For the six months, the company reported loss from operations of $22,282,000 compared with $10,777,000 for the same period a year ago. Net loss was $22,217,000 or $0.99 per basic and diluted share compared with $10,698,000 or $21.48 per basic and diluted share for the same period a year ago.

Tokai Pharmaceuticals, Inc. Announces Initiation of Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer

Tokai Pharmaceuticals, Inc. announced the initiation of ARMOR3-SV, the company's pivotal Phase 3 clinical trial of galeterone in men with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor (AR) that has been associated with non-responsiveness to commonly-used oral therapies for mCRPC. The company also announced that the components of the AR-V7 clinical trial assay have been finalized by its collaborator, Qiagen, and that global deployment of the assay is now underway. ARMOR3-SV will compare galeterone to Xtandi® (enzalutamide) in 148 mCRPC treatment-naïve patients whose prostate tumors express the AR-V7 splice variant. These truncated ARs are missing the C-terminal end of the AR that contains the ligand-binding domain, which is known as C-terminal loss. AR-V7 is the most common form of C-terminal loss. The pivotal trial will employ a precision medicine approach for selection of patients with the AR-V7 splice variant by using an AR-V7 clinical trial assay successfully optimized for global use by Qiagen. The primary endpoint of ARMOR3-SV is radiographic progression-free survival assessed by blinded independent central review. The design of ARMOR3-SV is aligned with feedback obtained from the U.S. Food and Drug Administration and the European Medicines Agency. ARMOR3-SV has been initiated at more than 15 sites in the United States, with site initiations in Canada and the United Kingdom anticipated later in June. Additional study centers throughout North America, Western Europe and Australia are expected to join the study in the coming months. In addition, with recent finalization of the components of the AR-V7 clinical trial assay, technology transfer activities and training of the global central laboratories are underway, and screening of eligible patients for the splice variant is expected to begin in July. The company expects topline data from ARMOR3-SV to be available by the end of 2016.

Tokai Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM

Tokai Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Lee H. Kalowski, Chief Financial Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKAI:US $12.05 USD +0.24

TKAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TKAI.
View Industry Companies

Industry Analysis


Industry Average

Valuation TKAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TOKAI PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at